瑞替普酶在急性心肌梗死治疗中的应用效果研究

Study on the Application Effect of Reteplase in the Treatment of Acute My-ocardial Infarction

目的对比研究急性心肌梗死患者通过瑞替普酶和尿激酶进行治疗的临床效果和安全性。方法方便选取该院在2015年3月—2016年2月期间诊治的60例急性心肌梗死患者,分成观察组与对照组(各30例),其中,对照组以尿激酶溶栓法进行治疗,而观察组则以瑞替普酶溶栓法进行治疗,观察与记录该两组患者在溶栓之后的12 h中出现并发症率、以及病死率、再通率和不良反应发生率等相关数据,然后进行对比。结果观察组患者在溶栓之后12 h内,出现的病死率与并发症率分别是0.00%、6.67%,与对照组相比差异无统计学意义;观察组的再通率和不良反应率分别是93.3%、6.67%,显著优于对照组(分别为46.7%、43.3%),两组患者的再通率和不良反应率对比,差异有统计学意义(P﹤0.05)。结论采用瑞替普酶进行治疗后,能有效提升了血管开通率,治疗效果要显著好于尿激酶,是对治疗急性心肌梗死患者进行治疗的一种安全性高、高效的溶栓药物,有着极大的临床应用价值。

Objective To study the treatment of patients with acute myocardial infarction by reteplase and urokinase.Methods Convenient selection 60 cases of acute myocardial infarction patients in our hospital during March 2015 to February 2016, divided into observation group and control group（each 30 cases）, the control group with urokinase method treatment, while the observation group was treated with reteplase thrombolytic method treatment, observing and recording the complications rate and mortality rate the recanalization rate, and incidence of adverse reactions and other related data in the12 h after thrombolysis in the patients of two groups were compared, and then. Results The patients in the observation group after thrombolysis in 12 h, mortality rate and complication rate appeared were 0.00%, 6.67%, Compared with the control group, the difference was not statistically significant; then observe rate pass rate and adverse reaction group were 93.3%and 6.67%, significantly better than the control group（46.7%, 43.3%）, the two groups of patients with recanalization rate and adverse reaction the rate of contrast, the difference was statistically significant（P〈 0.05）. Conclusion Reteplase after treatment, can effectively improve the patency rate, the treatment effect is significantly better than urokinase thrombolytic drugs is a safe and efficient treatment of high on treatment of patients with acute myocardial infarction, has great clinical application value.